The diagnosis of tuberculosis (TB) remains based on direct examination and solid cultures in the majority of countries with high TB prevalence ([@B41], [@B14], [@B40], [@B26]). Frequently, among paucibacillary patients such as children, human immunodeficiency virus (HIV) co-infected patients and patients with the extrapulmonary form of TB (regardless of age), smear-based microscopy is negative and the sputum-culture sensitivity is low ([@B10], [@B11], [@B29]). The use of molecular biology techniques has increased the ability to diagnose TB in paucibacillary TB ([@B4], [@B33], [@B2], [@B9], [@B22]) and has also shortened the time of diagnosis in relation to culturing in solid media, from four-six weeks to 24-48 h ([@B35], [@B20], [@B18]). The World Health Organization ([@B48]) conducted a comparative analysis of 19 different commercial kits for the molecular diagnosis of TB, using the standard protocol for each test and considering endemic and non-endemic countries. The results demonstrated a mean sensitivity of 27% and specificity greater than 90% in only 30% of the tests. In that study, TB-HIV co-infection reduced test performance, regardless of whether TB was endemic to the country. The Gen-Probe Amplified-MTD Direct Test kit was the first test for detecting DNA of the *Mycobacterium tuberculosis* complex to gain approval from the Food and Drug Administration (FDA) ([@B46]).

Xpert MTB/RIF (Cepheid, USA) is the first fully automated assay based on hemi-nested real-time polymerase chain reaction (PCR) for the detection of TB and rifampicin resistance performed directly on untreated sputum, with results obtained in less than 2 h. The assay was approved by the WHO in 2010 ([@B22], [@B26]).

COBAS^®^ Amplicor is a commercial test based on amplification, hybridisation and detection of the mycobacteria multicopy IS6110 insertion element that also has been approved by the FDA ([@B24], [@B45], [@B4], [@B19]). The Detect-TB Ampligenix Biotech Company kit is a test in the pre-clinical stage of development, which associates the amplification of the mycobacteria IS6110 sequence with the reversed hybridisation of the amplification product with probes complementary to internal sequences of the PCR-product, previously immobilised on microplates ([@B42], [@B27]). In the present study, we analysed the concordance of the Gen-Probe, Detect-TB, conventional homemade PCR and real-time PCR tests on pulmonary and blood samples from immunocompromised patients with upper respiratory complaints.

SUBJECTS, MATERIAL AND METHODS
==============================

In total, 165 blood and 194 sputum samples were collected from 181 different HIV-positive patients with upper respiratory complaints, regardless of TB suspicions, who were attended at the Correia Picanço Hospital and Oswaldo Cruz University Hospital, as shown in [Fig. 1](#f01){ref-type="fig"}. The samples were forwarded to Pernambuco Central Laboratory (LACEN-PE), where three unprocessed 0.5 mL-aliquots of sputum were transferred into sterile microtubes, inside a biosafety cabinet located in the mycology laboratory to assure no cross-contamination with cultivated *Mycobacterium*. Unprocessed sputum-aliquots and corresponding-patient blood samples were then forwarded to the molecular biology laboratory at Institute of Integrative Medicine Prof. Fernando Figueira (IMIP) for molecular testing. The remaining sputum samples underwent smear microscopy and culturing at the reference laboratory for TB diagnosis accredited by the Brazilian Ministry of Health located in the LACEN-PE. All samples were handled blindly by all technicians involved, from sample processing to results analysis.

Fig. 1: flowchart of clinical specimens tested for tuberculosis diagnosis. PCR: polymerase chain reaction.

*Microbiological analysis* - Acid-fast bacilli were detected by means of Ziehl-Neelsen staining on sputa smears. Sputa were decontaminated in accordance with the Petroff method and aliquots of 0.1 mL were placed in Lowenstein-Jansen solid medium. Blood samples did not undergo microbiological testing.

*Genomic DNA extraction* - The patients' blood samples underwent Ficoll-Paque Plus (GE Healthcare Bio-Sciences AB, Sweden) fractioning for leucocyte isolation. An aliquot of 10^6^ leucocytes and the first of the three sputum aliquots underwent genomic DNA extraction using proteinase K protocol. Briefly, the material was suspended in a 400 μL lysozyme solution (1.25 mg/mL) and was incubated at 37ºC for 16 h. Then, 75 μL of proteinase K (20 mg/mL) and 10% sodium dodecyl sulfate solution were added and the mixture was incubated at 65ºC. Next, 100 μL of 5 M NaCl and 100 μL of CTAB/NaCl were added and the samples were incubated at 65ºC. After 10 min of incubation, the DNA was extracted with phenol/chloroform solution and then concentrated by means of precipitation with isopropanol. The DNA precipitate was obtained through centrifugation at 16,000 *g* in a microcentrifuge, washed with 70% ethanol and dissolved in 50 μL of sterile water.

*Conventional PCR* - First, the genomic DNA underwent PCR for amplification of a target sequence on human DNA, acting as a positive control for the DNA extraction, thereby ensuring the absence of PCR inhibitors in the reaction. Next, PCR was performed with specific primers for amplification of the mycobacteria IS6110 genetic element. The total reaction volume was 50 μL and included 1.5 mM of MgCl~2~, 25 pmol of each primer (sense: 5'cgagctgcgcgatggcgaac and antisense: 5'taggtgctggtggtccgaag, synthesised by Invitrogen, USA), 200 µM of each dNTP and 1.25 units of DNA polymerase (Invitrogen). The reaction conditions were one cycle of 96ºC for 3 min, 30 cycles of 96ºC for 30 s for denaturation, 65ºC for 30 s for annealing, 72ºC for 30 s for extension and, finally, a cycle of 7 min at 72ºC using a thermocycler (Gradient Eppendorf, Germany). The PCR product was visualised on 2.5% agarose gel under ultraviolet light. The reaction was considered positive when the ethidium bromide-stained band corresponded to 245 bp.

*R* *eal-time PCR* - Quantitative PCR (qPCR) was performed using the same set of primers for IS6110 amplification as used in conventional PCR and an internal probe (Applied Biosystems, USA) in the presence of the TaqMan^®^ Universal PCR Master Mix and the DNA extracted from the patients' sputum or blood. The conditions for amplification of the IS6110 element were as follows: denaturation for 15 min at 95ºC followed by 45 cycles of 15 s at 94ºC and 60 s at 60ºC. In all PCR runs, standard curves were obtained using plasmid DNA encompassing the mycobacteria IS6110 sequence as the reaction positive control and all samples were tested in duplicate. Reaction with no DNA added was used as the negative control, also in duplicate. The reaction was run in an ABI 7500 machine with setup for absolute quantification, using a standard curve prepared with serial 10X dilution from 10 ng \[cycle threshold (Ct) = 14\] to 100 fg (Ct = 37) of plasmid control DNA in triplicate. The efficiency of the amplification reaction was 1.8, with a threshold set at 0.02 based on data from 26 different experiments. The slope was -3.84 and R = 0.999.

*Detect-TB* - The second sputum aliquot was tested for the presence of mycobacteria genome using the Detect-TB Ampligenix Biotech Company kit (Belo Horizonte, Brazil). Briefly, the cells were lysed to release the genomic DNA and to make it soluble. The extracted DNA was purified by means of silica resin capture in the presence of chaotropic agents, followed by successive washings and elution in a low-ionic-strength solution. Purified DNA underwent the IS6110 sequence amplification, using specific biotinylated primers. The PCR product was transferred into polystyrene microplates covalently immobilised with IS6110-probe. PCR product-bounded to the IS6110 immobilised probe was detected using a streptavidin-peroxidase/tetramethylbenzidine colorimetric system. Readings within the absorbance range from 0.225-0.275 were considered to be indeterminate. Values below 0.225 were considered to be negative and above 0.275 as positive.

*Gen-Probe amplified MTD* - The third frozen stored sputum aliquot underwent the Gen-Probe amplified MTD (San Diego, USA) testing. Firstly, the 500 μL samples were defrosted at room temperature (RT) in a biological cabinet. Then, the same volume of purifying solution of 2.9% sodium citrate and 4% NaOH was added and incubated for 15 min at RT. The samples were neutralised by adding 500 μL of phosphate buffer solution (pH 6.8). The volume of the samples was adjusted to 450 μL by centrifugation. All reagents and equipment used in the Gen-Probe protocol were as recommended by the manufacturer. Laboratory personnel trained by the company performed the protocol.

*Quality control* - The flux and transport of the biological samples between the different institutions involved in this project was carefully planned. The flux began in two public reference hospitals for HIV-infection treatment. These hospitals had a transport flow from their labs to the LACEN-PE, which is responsible for TB diagnosis in PE. The main problem was identifying the samples related to this research among the routine samples and therefore, we created small colourful forms to send with the research samples, working with the personnel of the LACEN-PE to identify the samples related to this study, to avoid processing exams in duplicate and possible specimen loss and to shorten the time of sample retention at the laboratory reception.

Another potential problem was related to where and how to aliquot the samples for the different tests. From the outset, we had decided to use the same samples for all tests given the possibility of different samples having different bacterial loads even when they are collected on the same sample day and the high likelihood that patients would not return on the second day to bring the first-daily sputum. To avoid possible cross-contamination with cultivated bacteria in the *Mycobacterium* facilities, the sputum samples were sent to the mycology lab because primarily manipulation was performed inside a biological cabinet in that laboratory after working hours. Three 0.5 mL-aliquots were prepared from each sputum specimen, which were frozen and sent to the molecular biology laboratory at another institution under refrigeration; the remaining sputa were sent to the mycobacteria facilities at LACEN-PE for microbiological analysis. Blood samples were sent to the molecular laboratory without manipulation.

All DNA extractions were performed at the Molecular Biology Laboratory of IMIP, inside a biosafety cabinet located in a room with restricted use to clinic sample handling. The PCR reactions were prepared in another room specifically designed for this purpose, free of biological samples and also inside a biosafety cabinet. The hybridisation procedures and the analysis of PCR products in gel were performed in the main area of the molecular biology laboratory.

For every conventional or real-time PCR run, two negative controls were run: one reaction was performed without the DNA template and another included genomic DNA of a healthy individual to identify possible non-specific DNA amplification.

To avoid interpretation bias, the research teams at the hospitals, LACEN-PE and the Molecular Biology Laboratory at IMIP, were different and the samples received a number at the hospital, a different number at LACEN-PE and yet another at the Molecular Biology laboratory. All patient identification numbers were noted in the patient database at the Molecular Biology laboratory; however, the codes were only broken for analysis at the end of the cohort study.

*Statistical analysis* - The sensitivity, specificity and the positive and negative predictive values (NPV) for each of the molecular tests evaluated for the diagnosis of TB in HIV-infected patients were calculated considering sputum culture as the gold standard, using a 2 x 2 table. The concordance between tests was evaluated using the kappa (k) test (Epi Info v.6.04 software). The receiver operating characteristic (ROC) curves were performed using MedCalc software, Ostend, Belgium.

*Ethics* - The Aggeu Magalhães Research Centre Institutional Review Board approved this study under the registration CAAE: 0007.0.095.000-07. The authors declare no conflict of interest and do not have a direct financial relation with the commercial identity mentioned in this manuscript.

RESULTS
=======

*Sputum samples* - Among 194 sputum samples from 181 different HIV-infected patients, 19 were culture-positive for *M. tuberculosis,* of which only eight were smear-positive.

Comparing the ROC curves of the different tests with sputum culture as the reference, the best results were associated with qPCR methodology ([Fig. 2A](#f02){ref-type="fig"}). qPCR presented 100% sensitivity, 96.7% specificity, 78.6% positive predictive value (PPV), 100% NPV and 97% accuracy ([Table I](#t01){ref-type="table"}). qPCR results demonstrated excellent concordance with culture (k = 0.864) and moderate concordance with Gen-Probe results (k = 0.586) ([Table II](#t02){ref-type="table"}). The Ct average of culture-positive, smear-positive sputa (32.5; range, 24.4-36.4) was similar to culture-positive, smear-negative sputa (33.4; range 30.3-35.4). Three samples presented culture-negative and positive-qPCR results, with Ct of 18, 19 and 21.

Fig. 2: receiver operating characteristic curve accuracy for molecular assay in tuberculosis (TB). A: accuracy estimated for four different molecular assays for TB testing in sputa using culture as gold-standard; B: accuracy of different cut-off set for TB testing in sputa using the Detect-TB assay; C: accuracy of conventional e quantitative polymerase chain reaction (qPCR) for TB diagnosis in blood.

TABLE IPositive (PPV) and negative (NPV) predictive values, sensitivity and specificity in samples using different molecular methods for the diagnosis of tuberculosis (TB) and sputum culture as gold standardReference x tests (sample)nPPV (%)NPV (%)Sensitivity (%)Specificity (%)Culture x PCR (sputum)19416.81 (9.4-29.5)100 (88.8-100)100 (67.9-100)46.3 (32.7-53.7)Culture x qPCR (sputum)10278.60 (48.8-94.3)100 (94.8-100)100 (67.9-100)96.70 (90-99.1)Culture x Detect-TB (sputum)19424.36 (12.2-37)100 (91.6-100)100 (67.9-100)66.30 (47.4-68.3)Culture x Gen-Probe (sputum)10264.30 (35.6-86)97.70 (91.3-99.6)81.80 (47.8-96.8)94.50 (87.1-98)Culture x PCR (blood)16513.8 (8.3-21.7)95.9 (89.9-99.3)88.90 (63.9-98.3)32 (24.7-40.2)Culture x qPCR (blood)10261.1 (36.1-81.7)100 (94.6-100)100 (67.9-100)92.30 (84.3-96.6)[^1]

TABLE IIConcordance between microbiological and molecular tests for diagnosis of tuberculosis (TB)Tests (sample)nAgreementKappaZpCulture X PCR (sputum)1940.4900.1392.760.0029Culture X qPCR (sputum)1020.9710.8648.800.0000Culture X Detect-TB (sputum)1940.6280.2313.650.0002Culture X Gen-Probe (sputum)1020.9310.6826.950.0000Culture X PCR (blood)1650.3820.0621.830.0337Culture X qPCR (blood)1020.9310.7547.590.0000PCR (sputum) X qPCR (sputum)1020.5200.1793.170.0007PCR (sputum) X Detect-TB (sputum)1020.6470.3013.150.0008PCR (sputum) X Gen-Probe (sputum)1020.4800.1121.990.0236qPCR (sputum) X Detect-TB (sputum)1020.6570.2944.190.0000qPCR (sputum) X Gen-Probe (sputum)1020.9020.5865.920.0000PCR (blood) X qPCR (blood)1020.4610.1572.950.0016qPCR (sputum) X qPCR (blood)1020.9020.6306.440.0000[^2]

Gen-Probe presented the second-best results with 81.8% sensitivity, 94.5% specificity, 64.3% PPV, 97.7% NPV and 93% accuracy. A substantial concordance between Gen-Probe and culture results was observed (k = 0.682)

Detect-TB demonstrated a sensitivity of 100%, but a specificity of 66.3%, corresponding to a PPV of 24.4%. ROC curves constructed with different cut-off values for testing Detect-TB showed that the best results for sensitivity and specificity occurred with a cut-off of 300 (100% sensitivity, 67.4% specificity) and 275 (100% sensitivity, 66.3% specificity). In this study, the cut-off used was 275, which was indicated by the manufacturer ([Fig. 2B](#f02){ref-type="fig"}). However, higher cut-off values might improve specificity with some compromised of sensitivity.

The lowest specificity was associated with conventional PCR performed from sputum (46.3%) and blood (32%) samples ([Table I](#t01){ref-type="table"}).

*Blood samples* - Concerning the molecular tests performed on the patients' blood samples, we only took into consideration samples from patients for whom sputum also had been collected for definition of the TB cases based on sputum culture.

Regarding blood samples, qPCR showed 100% sensitivity, 92.3% specificity, 61.1% PPV and 100% NPV in comparison to the sputum culture, whereas the in-house PCR showed sensitivity and specificity values of 88.9% and 32%, respectively ([Fig. 2C](#f02){ref-type="fig"}). A substantial concordance was observed between qPCR results obtained from blood and positive culture on sputum (k = 0.754) and also between qPCR results from blood and sputa (k = 0.630) ([Table II](#t02){ref-type="table"}).

DISCUSSION
==========

Many studies on the accuracy of molecular assays have been published on the diagnosis of pulmonary and non-pulmonary TB, both associated with smear-positive or smear-negative sputum samples and in HIV-infected or non-infected patients ([@B32], [@B22], [@B44], Walusimbi et al. 2013, [@B34]).

Smear-based microscopy is the most commonly used approach for pulmonary TB detection, demonstrating 70% sensitivity compared with culture associated with a clinical definition of the disease as the gold standard; however, in HIV-infected patients the smear-based sensitivity might be lower than 40% ([@B9], [@B21], [@B38]). In our study, the smear-based sensitivity was 42%. This was mainly related to the low bacillary load in sputum from HIV-infected patients ([@B28]).

We observed a great variation in the accuracies of the four tests evaluated considering that all were PCR-based assays and all used samples obtained from the same sputum. qPCR demonstrated superior performance with 97% accuracy, followed by Gen-Probe (93%), Detect-TB (70%) and conventional PCR (52%) for the detection of pulmonary TB infection from sputum. Recent publications regarding the molecular detection of pulmonary TB in HIV-infected patients also have shown variations in assay sensitivity (53-100%) between different or even the same assay ([Table III](#t03){ref-type="table"}).

TABLE IIIPerformance of different molecular tests for tuberculosis detection in HIV-infected patientsReferenceHIV-infected populationBiological sampleSampling (n)MethodologySensitivity (%)Specificity (%)PPV (%)NPV (%)Target suspected casesGold stantardThis paperRecife, BrazilBlood102qPCR10092.361.1100In and outpatientSolid cultureSputa102qPCR10096.778.6100102Gene-Probe81.894.564.397.7 Detect-TB66.310024.4100Albuquerque et al. (2014)Recife, BrazilSputa140qPCR87.298.997.693.9In and outpatientSolid cultureFeasey et al. (2013)Malawi, AfricaBlood104Xpert MTB/RIF2110010064In and outpatientSputum and solid cultureAbed Al-Darraji et al. (2013)Malaya, MalaysiaSputa125Xpert MTB/RIF53.310010094PrisonersLiquid cultureSilva et al. (2012)Santa Catarina, BrazilSputa85PCR59338710InpatientSolid cultureO'Grady et al. (2012)Lusaka, ZambiaSputa408Xpert MTB/RIF88.295.192.292.5InpatientLiquid culturePeter et al. (2012)Cape Town, South AfricaUrine113Xpert MTB/RIF4898\--InpatientLiquid cultureBalcells et al. (2012)Santiago, ChileSputa160Xpert MTB/RIF91.799.394.799.3InpatientLiquid cultureCarriquiry et al. (2012)Lima, PeruSputa131Xpert MTB/RIF97.897.795.798.8InpatientLiquid cultureScherer et al. (2011)Porto Alegre, BrazilSputa74PCR dot blot72858572In and outpatientSolid culture combined with clinicsPCR (agarose)42766853Lawn et al. (2011)Cape Town, South AfricaSputa445Xpert MTB/RIF73.399.294.894.8OutpatientLiquid cultureBoehme et al. (2011)Multi-siteSputa602Xpert MTB/RIF82.499.298.391.3OutpatientLiquid cultureMichelon et al. (2011)Multi-site, BrazilSputa47Detect-TB75100\--OutpatientCultureScott et al. (2011)Johannesburg, South AfricaSputa124Xpert MTB/RIF84969292OutpatientLiquid cultureMTBDR plus70969185Light Cycler Detection70989786Davis et al. (2011)Uganda, South AfricaSputa and bronchoalveolar lavage170MTB/RIF3995\--InpatientSolid culture[^3]

For TB detection in sputum, our qPCR assay presented 100% sensitivity and 96.7% specificity, comparable to the sensitivity of 80-95% and the specificity of 95-100% reported by others who also developed the TaqMan assay for detection of the IS6110 element ([@B17], [@B23], [@B3]). qPCR was positive for 100% of the smear-negative, culture-positive patients, providing earlier TB diagnosis for more TB-suspected patients than smear-based microscopy (7% vs. 4%) in HIV-infected patients. Improvement in pulmonary TB detection (25%) by means of molecular assay was reported in Chile, a TB non-endemic area, confirming the power of molecular tools in TB diagnosis for TB-control programs ([@B8]). Three patients with false-positive qPCR from sputum received empirical treatment for TB within six months of being tested and the clinical-symptom improvement confirmed their disease status. The withdrawal of a considerable (1.5 mL) amount of sputum for molecular analysis prior to sputum culturing might explained the absence of acid-fast bacillary growth on solid media, likely due to the loss of bacillary viability as a consequence of the sputum decontamination procedure ([@B25]).

The sensitivity and specificity of the Gen-Probe assay as reported in the literature ranges from 92-100% and from 85-100%, respectively, but in HIV-positive patients the sensitivity might be lower than 42% ([@B43], [@B15], [@B30], [@B36]). In our study, the performance of Gen-Probe was similar to qPCR (93% vs. 97% accuracy), with 81.8% sensitivity and 94.5% specificity for TB detection in sputum. Five false-positive cases were observed, two of whom received empirical TB treatment with improvement in clinical symptoms. In contrast to the qPCR assay, the Gen-Probe assay was associated with two false-negative cases, possibly due to the insufficient target DNA in the 0.5 mL sputum aliquot used, considering that the Gene-Probe protocol recommends the collection of 10 mL of sputum for decontamination and concentration procedures prior to use. The presence of PCR inhibitors in the sample may also have induced false-negative reactions with the Gen-Probe assay, which were not observed in the qPCR assay because, in this latter case, DNA was extracted using proteinase K digestion followed by a purification step performed with phenol-chloroform.

Cases identified as false-positives by the Detect-TB assay were responsible for the low specificity (66.3%) and PPV (24.4%) observed in our study. The causes for this performance are not clear, because a sensitivity of 75% and a specificity of 100% were reported using the same assay for TB detection in spontaneous sputum samples obtained from patients suspected of having TB ([@B25]). Difficulties in handling the kit, reagents' stability and delays in reading the reaction were considered. The handling was performed exclusively by laboratory personnel that had received training in executing the Detect-TB protocol. To read the samples, we placed the microplates on a cold surface to transport them to another laboratory in a connected building and thus some delay in reading might have contributed to these results, although we also should consider that some of these false-positive cases might indeed have been positive cases that had not been identified by culturing.

Our conventional PCR assay showed the poorest performance in sputum with 46.3% specificity. A published meta-analysis demonstrated a sensitivity variation of 32-92% with a mean of 72% and a specificity variation of 93-100% with a mean of 96% for the PCR simplex methodology for TB detection, in comparison with sputum culture results and clinical criteria ([@B37]). In our study, we used only culture as the gold standard. Nevertheless, the fact that qPCR and conventional PCR results were so divergent surprises us because both assays used the same primers and sample processing. The main differences were (i) qPCR used a fluorescent internal probe for accuracy improvement, which *per se* justifies this finding, while the conventional PCR did not have the probe hybridisation step, (ii) samples were run in duplicate or triplicate in qPCR, whereas a single sample normally was run for conventional PCR and (iii) qPCR data were measurable and positive cases were defined based on a standard curve, whereas in conventional PCR, the results were based on the identification of a band in agarose gel corresponding in size to the amplified PCR product. For all these reasons, the conventional PCR test may not be reliable ([@B2], [@B13]).

The difference in sample processing is a limitation for comparative analysis of the accuracy of different molecular assays for TB diagnosis. A study on the performance of the Xpert MTB/RIF test with an IS6110-TaqMan qPCR assay for the detection of mycobacteria in respiratory specimens processed by the standard procedure of decontamination and centrifugation reported no differences in overall sensitivity (79% vs. 84%, respectively) of both tests, which presented 100% sensitivity for smear-positive sputum, with no differences observed in smear-negative sputum sensitivity (57% vs. 68%, respectively) ([@B7]). Alternatively, [@B31] compared the performance of the Xpert MTB/RIF test using 1 mL of non-processed respiratory specimens with the COBAS TaqMan MTB assay using decontaminated-concentrated respiratory specimens obtained from \~5 mL sputum. The performance of both assays using culture results as the gold standard showed that the overall sensitivities of the Xpert (67.9%) and COBAS (71.4%) assays were similar. The Xpert sensitivity did not significantly differ between smear-positive and smear-negative (67% vs. 69%) sputum; however, the reduction from the 87% sensitivity in smear-positive sputum to 54% sensitivity in smear-negative sputum observed with the COBAS assay suggested that the sputum-decontamination processing included in the COBAS protocol contributed to reducing the bacillary viability in culture, even though the proportional sputum volume used was larger than that used in the Xpert test ([@B31]).

Comparing the performance of qPCR from sputum and blood samples of corresponding patients, the qPCR test exhibited an accuracy of 93% for the detection of TB in blood, showing good concordance with culture results (75%) and the qPCR results from sputum (63%). One explanation for this higher concordance with sputum culture than with qPCR testing of sputum was the high sensitivity of the qPCR test in sputum in relation to culture. The three cases of negative-culture and positive-qPCR results obtained from sputum were also negative-qPCR for blood, suggesting that mycobacteraemia might be associated with advanced disease. In this context, published data on the Xpert test for TB detection in blood revealed a 21% sensitivity and 100% specificity compared with sputum culture (56% concordance), but a positive association was reported between positive Xpert assay from blood samples and the mortality rate in HIV-infected patients ([@B16]). The main difference between the Xpert study and our protocol was in sample processing: we used leukocytes purified from 5 mL peripheral blood, whereas the Xpert protocol requires the collection of 18 mL of peripheral blood for cellular lyses and concentration into a 1 mL sample for introduction into the Xpert cartridge for diagnosis. In this context, it is noteworthy that blood components such as haem, lactoferrin and immunoglobulin G have been associated with reduced amplification yield ([@B5], [@B6]) and the efficient removal of PCR-inhibitors from blood-extracted DNA contributes to improved sensitivity of the PCR-based diagnostic assay.

In HIV-infected patients, confirmation of the diagnosis of pulmonary TB from sputum is more difficult due to the low bacillary load in sputum and this difficulty is also associated with external factors that influence the sample quality, such as inadequate sputum collection, sample transportation, time delays in sample processing and the methodology employed. We believe that qPCR is one of the molecular tests that should be considered as a tool for the detection of pulmonary TB in smear-negative patients.

[^1]: Detect-TB is a test in developing and Gen-Probe a commercial molecular test for TB diagnosis. Blood and sputum samples were collected on the same day. PCR: in house polymerase chain reaction; qPCR: quantitative real-time PCR.

[^2]: Detect-TB is a test in developing and Gen-Probe a commercial molecular test for TB diagnosis. Blood and sputum samples were collected on the same day. Culture was performed only in sputa. PCR: in house polymerase chain reaction; qPCR: quantitative real-time PCR.

[^3]: HIV: human immunodeficiency virus; NPV: negative predictive value; PCR: in house polymerase chain reaction; PPV: positive predictive value; qPCR: quantitative real-time PCR.
